Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: L.D. Collins & Co. Ltd., 1st Floor, Gallery Court, 28 Arcadia Avenue, London, N3 2FG, UK
Cyclogest is indicated for the:
200mg daily to 400mg twice a day, by vaginal or rectal insertion. For premenstrual syndrome commence treatment on day 14 of menstrual cycle and continue treatment until onset of menstruation. If symptoms are present at ovulation commence treatment on day 12.
Use in special populations: There is no experience with use of Cyclogest in patients with impaired liver or renal function.
Paediatric population: There is no relevant use of Cyclogest in the paediatric population.
Elderly: No clinical data have been collected in patients over age 65.
There is a wide margin of safety with Cyclogest pessaries, but overdosage may produce euphoria or dysmenorrhoea.
Three years from the date of manufacture.
Shelf-life after dilution/reconstitution: Not applicable.
Shelf-life after first opening: Not applicable.
Store below 25°C in a dry place.
The product may be supplied in strip packs contained in cartons:
Carton: White backed folding box board printed on white.
Strip pack: Aluminium foil lacquer-laminated to 20µm polypropylene foil and coated on the reverse with polythene (20mg/m²). The alternative is thermoplastic film and laminated PVC to 95µm and polyethylene to 27-30µm.
Pack sizes: 5s, 12s, 15s
Not applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
